We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Phreesia (PHR) Q3 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Phreesia (PHR - Free Report) to post quarterly earnings of $0.00 per share in its upcoming report, which indicates a year-over-year increase of 100%. Revenues are expected to be $120.13 million, up 12.5% from the year-ago quarter.
Over the last 30 days, there has been an upward revision of 50% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Phreesia metrics that Wall Street analysts commonly model and monitor.
The collective assessment of analysts points to an estimated 'Revenus- Subscription and related services' of $55.44 million. The estimate points to a change of +12.3% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenus- Network solutions' should arrive at $37.46 million. The estimate indicates a change of +14.5% from the prior-year quarter.
The consensus among analysts is that 'Revenus- Payment processing fees' will reach $27.25 million. The estimate indicates a year-over-year change of +10.3%.
Analysts predict that the 'Average healthcare services Clients' will reach 4,530 . Compared to the current estimate, the company reported 4,237 in the same quarter of the previous year.
The consensus estimate for 'Patient payment volume' stands at $1.16 billion. The estimate compares to the year-ago value of $1.08 billion.
Analysts' assessment points toward 'Payment facilitator volume percentage' reaching 81.3%. The estimate compares to the year-ago value of 81.0%.
Over the past month, Phreesia shares have recorded returns of -10.6% versus the Zacks S&P 500 composite's -0.1% change. Based on its Zacks Rank #2 (Buy), PHR will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stay Ahead of the Game With Phreesia (PHR) Q3 Earnings: Wall Street's Insights on Key Metrics
Wall Street analysts expect Phreesia (PHR - Free Report) to post quarterly earnings of $0.00 per share in its upcoming report, which indicates a year-over-year increase of 100%. Revenues are expected to be $120.13 million, up 12.5% from the year-ago quarter.
Over the last 30 days, there has been an upward revision of 50% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Phreesia metrics that Wall Street analysts commonly model and monitor.
The collective assessment of analysts points to an estimated 'Revenus- Subscription and related services' of $55.44 million. The estimate points to a change of +12.3% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenus- Network solutions' should arrive at $37.46 million. The estimate indicates a change of +14.5% from the prior-year quarter.
The consensus among analysts is that 'Revenus- Payment processing fees' will reach $27.25 million. The estimate indicates a year-over-year change of +10.3%.
Analysts predict that the 'Average healthcare services Clients' will reach 4,530 . Compared to the current estimate, the company reported 4,237 in the same quarter of the previous year.
The consensus estimate for 'Patient payment volume' stands at $1.16 billion. The estimate compares to the year-ago value of $1.08 billion.
Analysts' assessment points toward 'Payment facilitator volume percentage' reaching 81.3%. The estimate compares to the year-ago value of 81.0%.
View all Key Company Metrics for Phreesia here>>>Over the past month, Phreesia shares have recorded returns of -10.6% versus the Zacks S&P 500 composite's -0.1% change. Based on its Zacks Rank #2 (Buy), PHR will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .